Retatrutide: The Triple Hormone Agonist Pushing Weight Loss Beyond the GLP-1 Era

For much of the last decade, the story of peptide-based weight loss has been linear: semaglutide outperformed older GLP-1 drugs, then tirzepatide outperformed semaglutide. Now a third compound is in phase 3 trials, retatrutide, and its phase 2 data suggests the ceiling may be higher still.

Understanding why requires looking not just at the numbers, but at what adding a third receptor target actually does to the underlying biology.

What Retatrutide Is

Retatrutide (development code LY3437943) is a synthetic 39-amino-acid peptide engineered by Eli Lilly. It activates three receptors simultaneously: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR). This is why it is often called a “triple agonist” or, informally, a GLP-3, though that shorthand is colloquial rather than pharmacological.

The peptide is conjugated to a fatty diacid moiety, which binds albumin in the bloodstream and extends its half-life to roughly six days. That enables once-weekly subcutaneous injection, the same dosing schedule as semaglutide and tirzepatide.

Retatrutide is structurally built from a GIP backbone. It exhibits greater potency at the human GIP receptor than at the GLP-1 and glucagon receptors, where its activity runs lower than the respective endogenous ligands, a deliberate design choice to balance the three effects without pushing any single axis too hard.

How the Three Mechanisms Work Together

Each receptor does something distinct.

GLP-1 receptor activation is what drove the semaglutide story. It slows gastric emptying, suppresses appetite via hypothalamic signaling, enhances glucose-dependent insulin secretion, and suppresses glucagon after meals. Satiety is the primary downstream effect.

GIP receptor activation adds incretin synergy, it amplifies insulin secretion in a glucose-dependent way and may act on adipose tissue and the central nervous system to complement GLP-1’s appetite effects. Tirzepatide already established that combining GIP and GLP-1 agonism pushes outcomes past what GLP-1 alone can deliver.

Glucagon receptor activation is the genuinely novel element. Glucagon raises blood glucose, which is why it was historically viewed as the wrong target for metabolic drugs. But when paired with robust GLP-1 receptor activation that prevents hyperglycemia, glucagon agonism does something useful: it increases energy expenditure through thermogenesis, promotes hepatic fat oxidation, and accelerates lipolysis. The net effect is enhanced caloric burn on top of the appetite reduction driven by the other two receptors.

The hypothesis, and the phase 2 data largely bear it out, is that this third lever produces weight loss beyond what appetite suppression alone can achieve.

What the Phase 2 Trial Found

The landmark phase 2 data were published in the New England Journal of Medicine in 2023. The randomized, double-blind, placebo-controlled trial enrolled adults with obesity or overweight without diabetes and tested four doses (1, 4, 8, and 12 mg) over 48 weeks.

At 24 weeks, the 12 mg dose group had achieved a mean weight reduction of 17.5%, or approximately 41 pounds. That figure was already comparable to semaglutide’s 48-to-68-week outcomes in the STEP-1 trial (~15% mean body weight reduction at 68 weeks).

The 48-week results were more striking. With the 12 mg dose:

• Mean weight reduction reached 24.2%, approximately 57.8 pounds (26.2 kg)
• 100% of participants lost at least 5% of body weight
• 93% lost at least 10%
• 83% lost at least 15%

Critically, weight loss at 48 weeks had not plateaued. The curves were still descending at the trial’s end, suggesting that longer treatment might yield additional benefit, a behavior that also set tirzepatide apart from semaglutide.

For context: tirzepatide’s phase 3 SURMOUNT-1 trial recorded a mean 22.5% weight loss at 72 weeks in the highest-dose group. Retatrutide matched or exceeded that at 48 weeks in a phase 2 setting, with a smaller sample and a shorter treatment window.

The Liver Fat Finding

A separate phase 2a study published in Nature Medicine in June 2024 examined retatrutide in patients with metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD). Participants receiving retatrutide saw up to 82% reduction in liver fat, an outcome that is striking even by the standards of a field where GLP-1 drugs have already shown hepatic benefit.

This is likely the glucagon component at work. Glucagon receptor activation directly promotes hepatic fat oxidation, giving retatrutide a lever on liver metabolism that dual agonists lack.

Side Effects: Familiar Territory

The tolerability profile in phase 2 was broadly consistent with other incretin-based therapies. Nausea, vomiting, decreased appetite, and diarrhea were the most common adverse events, with incidence rising with dose and declining over time as is typical with this drug class. Heart rate increased modestly in higher-dose groups, a signal worth tracking given the glucagon component, but no new safety signals emerged that distinguished retatrutide sharply from semaglutide or tirzepatide.

Where Phase 3 Stands in 2026

Eli Lilly launched the TRIUMPH phase 3 program across multiple trials. TRIUMPH-4 reported the first successful phase 3 readout in December 2025. TRIUMPH-1 reported its primary endpoint in May 2026. Additional readouts from TRIUMPH-2 and TRIUMPH-3 are expected throughout the rest of 2026.

Retatrutide is not FDA approved as of July 2026 and is not available by prescription. Lilly has not yet submitted a Biologics License Application; the company expects to complete the phase 3 program in late 2026 or early 2027 before an FDA submission.

For people currently using GLP-1 therapies, retatrutide is not a substitute available through compounding pharmacies or off-label prescribing in the way that semaglutide became widely accessible. It remains strictly investigational.

What This Means for the Weight Loss Landscape

Retatrutide represents the clearest evidence yet that targeting more metabolic pathways simultaneously produces additive rather than redundant effects. Adding glucagon receptor agonism to the GIP/GLP-1 combination appears to provide a meaningful additional boost, not from appetite suppression alone, but from increased energy expenditure.

If phase 3 confirms phase 2, retatrutide could challenge tirzepatide’s position as the highest-efficacy peptide-based weight loss therapy. More importantly, it suggests that the biological ceiling for pharmacological weight management is higher than current approved drugs have yet demonstrated.

This is a space worth following closely. The tools being developed, whatever their eventual regulatory status, are providing extraordinary insight into the metabolic circuitry that governs body weight. Understanding that circuitry is increasingly the foundation for any serious conversation about sustained, meaningful weight loss.

This article is for educational purposes only. Retatrutide is an investigational compound that is not approved by the FDA. Nothing here constitutes medical advice. Consult a licensed clinician before considering any peptide or weight loss therapy. See our Provider Directory for telehealth providers who work with approved GLP-1 therapies.